SYUMIX | Syntax US Medical Innovation Index

Index Description

The Syntax US Medical Innovation Index comprises up to 50 equally weighted US-listed companies engaged in the biotechnology and biopharma industry. The Index's universe of companies is maintained with the help of company classification data structured in Syntax's proprietary Functional Information System (FIS)®, which draws primarily from audited annual reports (e.g., SEC Form 10-K filings) and secondarily from unaudited documents (e.g., investor presentations, company websites, news articles) to allow granular groupings and comparisons of companies by the characteristics of their various product lines. To qualify, a company must pass the Index's screens for size and liquidity, and must own at least one drug that is in an FDA Phase II or Phase III trial and has a special FDA designation or a milestone in the near future.

Index Facts

Number of Constituents 48
Weighting Methodology Equal
Rebalancing Frequency Quarterly
Currency USD
Exchange Symbol/Ticker SYUMIX
Index Inception Date October 21, 2022
Total Return Index Value as of 02/23/2024 1277.84

Index Performance

Multi-Horizon Returns % as of 2023-12-31
YTD 4Q23 1Y 3Y 5Y 7Y 10Y Since 10.21.22
US Medical Innovation16.3228.9416.32----16.58
Annual Index Performance % as of 2023-12-31
2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
US Medical Innovation16.32---------
Index Statistics as of 2023-12-31
Vol. Sharpe Ratio
US Medical Innovation34.10.32
Index Fundamentals as of 2023-12-31
Dividend Yield P / E Ratio P / B Ratio
US Medical Innovation0.18NA4.92
Top Holdings as of 2023-12-31
Click on a company name to view more information on key statistics, classification and more. Premium data requires an Affinity login.
Company Weight (%)
Immunitybio Inc 5.68
TG Therapeutics Inc 3.78
Arvinas Inc 3.62
Iovance Biotherapeutics Inc 3.32
RAPT Therapeutics Inc 3.01
Ardelyx Inc 2.76
Rhythm Pharmaceuticals Inc 2.73
Viridian Therapeutics Inc 2.61
Rocket Pharmaceuticals Inc 2.53
Kura Oncology Inc 2.52